Theratechnologies Stock Jumps After Q2 Earnings, FY22 Guidance

  • Theratechnologies Inc THTX issued an update on the dose escalation portion of the TH1902 Phase 1 safety study. 
  • 18 heavily pretreated patients were enrolled. Two of those patients remain on treatment. 
  • Following the safety observations at 420 mg/m2, the dose of TH1902 was decreased to 300 mg/m2 and was expanded to a total of 6 patients. 
  • No Dose Limiting Toxicities were observed during the first cycle. The dose of 300 mg/m2 was selected to continue the basket part of the study. 
  • Signs of efficacy have been observed in three heavily pretreated patients.
  • Confirmed partial response in one prostate cancer patient with a 53% overall reduction in target lesions after three cycles of TH1902 at 300 mg/m2 was observed.
  • Stabilized disease was observed in prostate and endometrial cancer patients with a measurable reduction in target lesion sizes.
  • The company said that out-licensing development and commercialization rights for TH1902 in Greater China continue.
  • Q2 Earnings: Theratechnologies reported sales of $19.3 million, +8.3% Y/Y. The company tightened FY22 sales guidance to $79 million - $82 million (compared to the earlier range of $79-$84 million). The adjustments reflect our updated expectations from Europe.
  • Price Action: THTX shares are up 11.7% at $2.29 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!